Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


Articles published in Curr Opin Urol

Retrieve available abstracts of 70 articles:
HTML format



Single Articles


    September 2022
  1. CROCEROSSA F, Autorino R, Carbonara U, Cantiello F, et al
    Extent of lymph node dissection and impact on survival in radical cystectomy for advanced bladder cancer.
    Curr Opin Urol. 2022 Sep 14. pii: 00042307-990000000-00040.
    PubMed     Abstract available


  2. ESCOTT M, Avulova S, Bree KK, Westerman ME, et al
    Radical cystectomy and women's sexual health - can we do better?
    Curr Opin Urol. 2022;32:545-553.
    PubMed     Abstract available


  3. PIJPERS OM, de Jong JJ, Zuiverloon TCM, Boormans JL, et al
    RNA-based urinary assays for non-muscle invasive bladder cancer.
    Curr Opin Urol. 2022;32:523-530.
    PubMed     Abstract available


  4. COMPERAT E, Oszwald A, Wasinger G, Klager J, et al
    Molecular uropathology and cancer genetics for the urologist: key findings for classification and diagnosis.
    Curr Opin Urol. 2022;32:451-455.
    PubMed     Abstract available


  5. LAUKHTINA E, Pradere B, Lemberger U, Karakiewicz PI, et al
    Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder.
    Curr Opin Urol. 2022;32:561-566.
    PubMed     Abstract available


  6. SHEYBAEE MOGHADDAM F, Ghoreifi A, Djaladat H
    Comparative performance of the different orthotopic urinary diversions.
    Curr Opin Urol. 2022;32:554-560.
    PubMed     Abstract available


  7. KIM SH, Lerner SP
    Drug instillation in the management of urinary tract urothelial carcinoma.
    Curr Opin Urol. 2022;32:531-535.
    PubMed     Abstract available


  8. MARTINI A, Fallara G, Ploussard G, Pradere B, et al
    Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma.
    Curr Opin Urol. 2022;32:500-503.
    PubMed     Abstract available


  9. COMPERAT E, Wasinger G, Oszwald A, Shariat SF, et al
    Brief update of the new WHO classification for urothelial carcinoma.
    Curr Opin Urol. 2022;32:511-516.
    PubMed     Abstract available


  10. MESSINA E, Pisciotti ML, Pecoraro M, Borrelli A, et al
    The use of MRI in urothelial carcinoma.
    Curr Opin Urol. 2022;32:536-544.
    PubMed     Abstract available


    July 2022
  11. VON DEIMLING M, Pallauf M, Bianchi A, Laukhtina E, et al
    Active surveillance for non-muscle-invasive bladder cancer: fallacy or opportunity?
    Curr Opin Urol. 2022 Jul 25. pii: 00042307-990000000-00032.
    PubMed     Abstract available


  12. LONATI C, Simeone C, Suardi N, Briganti A, et al
    Micropapillary bladder cancer: an evolving biology.
    Curr Opin Urol. 2022 Jul 19. pii: 00042307-990000000-00030.
    PubMed     Abstract available


  13. SCHOBER JP, Plimack E, Geynisman D, Zibelman M, et al
    The past, present, and future of pT0 in bladder cancer clinical trials.
    Curr Opin Urol. 2022 Jul 19. pii: 00042307-990000000-00026.
    PubMed     Abstract available


  14. SORIA F, Dutto D, Gontero P
    Clinical and biological markers for risk-stratification of T1 high-grade non-muscle invasive bladder cancer.
    Curr Opin Urol. 2022 Jul 15. pii: 00042307-990000000-00019.
    PubMed     Abstract available


  15. COMPERAT E, Wasinger G, Oszwald A, Pradere B, et al
    Nonmuscle-invasive bladder cancer, old problems, new insights.
    Curr Opin Urol. 2022;32:352-357.
    PubMed     Abstract available


    June 2022
  16. VARTOLOMEI MD, Ferro M, Roth B, Teoh JY, et al
    Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update.
    Curr Opin Urol. 2022 Jun 27. pii: 00042307-990000000-00015.
    PubMed     Abstract available


    January 2022
  17. REGNIER S, Califano G, Elalouf V, Albisinni S, et al
    Restaging transurethral resection in ta high-grade nonmuscle invasive bladder cancer: a systematic review.
    Curr Opin Urol. 2022;32:54-60.
    PubMed     Abstract available


  18. HUSSEIN AA, Li Q, Guru KA
    Robot-assisted radical cystectomy: surgical technique, perioperative and oncologic outcomes.
    Curr Opin Urol. 2022;32:116-122.
    PubMed     Abstract available


  19. BERNDL F, Hassler MR
    Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.
    Curr Opin Urol. 2022;32:48-53.
    PubMed     Abstract available


  20. LONATI C, Moschini M, Simeone C, Spiess PE, et al
    Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma.
    Curr Opin Urol. 2022;32:40-47.
    PubMed     Abstract available


    December 2021
  21. ENIKEEV D, Babjuk M, Shpikina A, Shariat S, et al
    En bloc resection for nonmuscle-invasive bladder cancer: selecting a proper laser.
    Curr Opin Urol. 2021 Dec 24. pii: 00042307-900000000-98808.
    PubMed     Abstract available


    November 2021
  22. CICIONE A, Lombardo R, D'Annunzio S, De Nunzio C, et al
    Success factors for abdominal wall diversions, including ureterocutaneostomy.
    Curr Opin Urol. 2021;31:544-549.
    PubMed     Abstract available


  23. HEESAKKERS JPFA, Witjes F
    Editorial: Medical, technical and functional aspect of various types of urinary diversion.
    Curr Opin Urol. 2021;31:542-543.
    PubMed    


  24. GRAUER R, Wiklund NP
    Update on robotic cystectomy.
    Curr Opin Urol. 2021;31:537-541.
    PubMed     Abstract available


  25. LIEDBERG F, Bobjer J
    Urinary diversions for benign and oncologic indications: what did we learn about short term complications in the last 24 months?
    Curr Opin Urol. 2021;31:556-561.
    PubMed     Abstract available


  26. NUIJENS ST, Cobussen-Boekhorst H, Heesakkers JPFA, Witjes JA, et al
    Patient-reported outcomes and health-related quality of life after urinary diversions.
    Curr Opin Urol. 2021;31:574-579.
    PubMed     Abstract available


  27. VAN 'T HOF MEM, Bruins HM, van Roermund JGH
    Management of upper urinary tract problems after radical cystectomy for urothelial carcinoma: tips and tricks.
    Curr Opin Urol. 2021;31:570-573.
    PubMed     Abstract available


    July 2021

  28. Bladder-preserving strategies for Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?: Erratum.
    Curr Opin Urol. 2021;31:436.
    PubMed    


    June 2021
  29. JANSSEN GWB, Ramkumar RR, Lee BH, van der Heijden AG, et al
    Orthotopic urinary diversions after radical cystectomy for bladder cancer: lessons learned last decade.
    Curr Opin Urol. 2021 Jun 25. pii: 00042307-900000000-98856.
    PubMed     Abstract available


    May 2021
  30. CHAN EO, Pradere B, Teoh JY
    The use of artificial intelligence for the diagnosis of bladder cancer: a review and perspectives.
    Curr Opin Urol. 2021 May 11. pii: 00042307-900000000-98866.
    PubMed     Abstract available


  31. ZIMMERMANN K, Mostafaei H, Heidenreich A, Schmelz HU, et al
    Health-related quality of life in bladder cancer patients: bladder cancer-specific instruments and domains. Part 2.
    Curr Opin Urol. 2021 May 10. pii: 00042307-900000000-98868.
    PubMed     Abstract available


  32. SCHUETTFORT VM, Pradere B, Comperat E, Abufaraj M, et al
    Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review.
    Curr Opin Urol. 2021 May 10. pii: 00042307-900000000-98867.
    PubMed     Abstract available


  33. ZIMMERMANN K, Mostafaei H, Heidenreich A, Schmelz HU, et al
    Part I. Health-related quality of life in bladder cancer patients: general and cancer-specific instruments.
    Curr Opin Urol. 2021 May 6. pii: 00042307-900000000-98874.
    PubMed     Abstract available


  34. PACKIAM VT, Richards J, Schmautz M, Heidenreich A, et al
    The current landscape of salvage therapies for patients with bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2021;31:178-187.
    PubMed     Abstract available


  35. ABUFARAJ M, Al-Ani A, AlQudah A, Shariat SF, et al
    Surgical intervention in patients with urothelial carcinoma of the bladder and lymph node metastasis.
    Curr Opin Urol. 2021;31:220-225.
    PubMed     Abstract available


    April 2021
  36. PINAR U, Pradere B, Roupret M
    Artificial intelligence in bladder cancer prognosis: a pathway for personalized medicine.
    Curr Opin Urol. 2021 Apr 20. pii: 00042307-900000000-98882.
    PubMed     Abstract available


    December 2020
  37. HUGAR LA, Gilbert SM, Sexton WJ, Kamat AM, et al
    Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2020;Publish Ahead of Print.
    PubMed     Abstract available


    September 2020

  38. Bladder-preserving strategies for Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?: Erratum.
    Curr Opin Urol. 2020;30:746.
    PubMed    


  39. SARI MOTLAGH R, Mori K, Aydh A, Karakiewicz PI, et al
    Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy.
    Curr Opin Urol. 2020;30:701-710.
    PubMed     Abstract available


  40. REBHAN K, Ertl IE, Shariat SF, Grollman AP, et al
    Aristolochic acid and its effect on different cancers in uro-oncology.
    Curr Opin Urol. 2020;30:689-695.
    PubMed     Abstract available


    July 2020
  41. MORI K, Mostafaei H, Abufaraj M, Yang L, et al
    Smoking and bladder cancer: review of the recent literature.
    Curr Opin Urol. 2020 Jul 20. doi: 10.1097/MOU.0000000000000804.
    PubMed     Abstract available


  42. EINERHAND SMH, van Gennep EJ, Mertens LS, Hendricksen K, et al
    18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer.
    Curr Opin Urol. 2020 Jul 20. doi: 10.1097/MOU.0000000000000798.
    PubMed     Abstract available


  43. GUST KM, Rebhan K, Resch I, Shariat SF, et al
    Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer.
    Curr Opin Urol. 2020;30:547-556.
    PubMed     Abstract available


  44. ERTL IE, Shariat SF, Mostafaei H, Ilijazi D, et al
    Fibroblast growth factor receptors across urothelial carcinoma landscape.
    Curr Opin Urol. 2020;30:557-565.
    PubMed     Abstract available


  45. BRONIMANN S, Lemberger U, Bruchbacher A, Shariat SF, et al
    Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
    Curr Opin Urol. 2020;30:519-526.
    PubMed     Abstract available


  46. LIU B, Welk B
    Urological malignancies in neurogenic patients.
    Curr Opin Urol. 2020;30:501-506.
    PubMed     Abstract available


    May 2020
  47. SORIA F, Giordano A, Shariat SF, Gontero P, et al
    Bladder sparing landscape for bacillus Calmette-Guerin unresponsive bladder cancer.
    Curr Opin Urol. 2020 May 13. doi: 10.1097/MOU.0000000000000789.
    PubMed     Abstract available


  48. PRADERE B, Schuettfort V, Mori K, Quhal F, et al
    Management of de-novo urothelial carcinoma in transplanted patients.
    Curr Opin Urol. 2020;30:467-474.
    PubMed     Abstract available


  49. JAHRREISS V, Pradere B, Laukhtina E, Mori K, et al
    Catalog of exogenous risk factors for bladder carcinogenesis.
    Curr Opin Urol. 2020;30:449-456.
    PubMed     Abstract available


  50. CARANDO R, Shariat SF, Moschini M, D'Andrea D, et al
    Ureteral and urethral recurrence after radical cystectomy: a systematic review.
    Curr Opin Urol. 2020;30:441-448.
    PubMed     Abstract available


  51. KHETRAPAL P, Conroy S, Kelly JD, Catto JWF, et al
    Comparing open-radical cystectomy and robot-assisted radical cystectomy: current status and analysis of the evidence.
    Curr Opin Urol. 2020;30:400-406.
    PubMed     Abstract available


  52. SUBIELA JD, Rodriguez Faba O, Guerrero-Ramos F, Aumatell J, et al
    Carcinoma in situ of the bladder: why is it underdetected?
    Curr Opin Urol. 2020;30:392-399.
    PubMed     Abstract available


  53. SORIA F, Giordano A, Gontero P
    Transurethral resection of bladder tumor and the need for re-transurethral resection of bladder tumor: time to change our practice?
    Curr Opin Urol. 2020;30:370-376.
    PubMed     Abstract available


  54. TERRITO A, Bevilacqua G, Meneghetti I, Mercade A, et al
    En bloc resection of bladder tumors: indications, techniques, and future directions.
    Curr Opin Urol. 2020;30:421-427.
    PubMed     Abstract available


  55. LOTAN Y
    Novel technologies that change the diagnostic and treatment paradigm in urology: standard turbt remains the standard.
    Curr Opin Urol. 2020;30:477-478.
    PubMed    


  56. ALMASSI N, Bochner BH
    Ileal conduit or orthotopic neobladder: selection and contemporary patterns of use.
    Curr Opin Urol. 2020;30:415-420.
    PubMed     Abstract available


    April 2020
  57. SARI MOTLAGH R, Pradere B, Mori K, Miura N, et al
    Bladder-preserving strategies for Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?
    Curr Opin Urol. 2020 Apr 16. doi: 10.1097/MOU.0000000000000769.
    PubMed     Abstract available


    March 2020
  58. FABA OR, Palou J
    Emerging approaches and future perspectives in nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2020 Mar 19. doi: 10.1097/MOU.0000000000000766.
    PubMed    


  59. SUNG HH, Lerner SP
    Utility of lymphadenectomy in bladder cancer: where do we stand?
    Curr Opin Urol. 2020 Mar 19. doi: 10.1097/MOU.0000000000000750.
    PubMed     Abstract available


  60. CIPOLLARI S, Carnicelli G, Bicchetti M, Campa R, et al
    Utilization of imaging for staging in bladder cancer: is there a role for MRI or PET-computed tomography?
    Curr Opin Urol. 2020 Mar 9. doi: 10.1097/MOU.0000000000000743.
    PubMed     Abstract available


  61. LENFANT L, Aminsharifi A, Seisen T, Roupret M, et al
    Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer.
    Curr Opin Urol. 2020 Mar 5. doi: 10.1097/MOU.0000000000000740.
    PubMed     Abstract available



  62. Bacillus Calmette-Guerin (BCG) treatment of bladder cancer: a systematic review and commentary on recent publications: Erratum.
    Curr Opin Urol. 2020;30:281.
    PubMed    


    February 2020
  63. FANKHAUSER CD, Teoh JY, Mostafid H
    Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guerin shortage.
    Curr Opin Urol. 2020 Feb 25. doi: 10.1097/MOU.0000000000000739.
    PubMed     Abstract available


  64. WITJES JA
    Developments in the follow-up of nonmuscle invasive bladder cancer: what did we learn the last 24 months: a critical review.
    Curr Opin Urol. 2020 Feb 25. doi: 10.1097/MOU.0000000000000741.
    PubMed     Abstract available


    November 2019
  65. MORI K, D'Andrea D, Enikeev DV, Egawa S, et al
    En bloc resection for nonmuscle invasive bladder cancer: review of the recent literature.
    Curr Opin Urol. 2019 Nov 12. doi: 10.1097/MOU.0000000000000697.
    PubMed     Abstract available


    May 2019
  66. POZO C, Shariat SF, D'Andrea D, Fajkovic H, et al
    Enhanced Recovery after Radical Cystectomy.
    Curr Opin Urol. 2019;29:227-238.
    PubMed     Abstract available


  67. BURG ML, Daneshmand S
    Frailty and preoperative risk assessment before radical cystectomy.
    Curr Opin Urol. 2019;29:216-219.
    PubMed     Abstract available


  68. HASSLER MR, Shariat SF, Soria F
    Salvage therapeutic strategies for bacillus Calmette-Guerin failure.
    Curr Opin Urol. 2019;29:239-246.
    PubMed     Abstract available


  69. CACCIAMANI GE, Rajarubendra N, Artibani W, Gill IS, et al
    Robotic intracorporeal urinary diversion: state of the art.
    Curr Opin Urol. 2019;29:293-300.
    PubMed     Abstract available


    January 2019
  70. BANDINI M, Fossati N, Briganti A
    Nomograms in urologic oncology, advantages and disadvantages.
    Curr Opin Urol. 2019;29:42-51.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: